Potential effects of omega-3 fatty acids on anemia and inflammatory markers in maintenance hemodialysis patients by Afshin Gharekhani et al.
Gharekhani et al. DARU Journal of Pharmaceutical Sciences 2014, 22:11
http://www.darujps.com/content/22/1/11RESEARCH ARTICLE Open AccessPotential effects of omega-3 fatty acids on anemia
and inflammatory markers in maintenance
hemodialysis patients
Afshin Gharekhani1, Mohammad-Reza Khatami2, Simin Dashti-Khavidaki2,3*, Effat Razeghi2, Alireza Abdollahi4,
Seyed-Saeed Hashemi-Nazari5 and Mohammad-Ali Mansournia6Abstract
Background: Anemia is a common complication among hemodialysis (HD) patients. Although intravenous iron and
erythropoiesis-stimulating agents revolutionized anemia treatment, about 10% of HD patients show suboptimal
response to these agents. Systemic inflammation and increased serum hepcidin level may contribute to this
hyporesponsiveness. Considering the anti-inflammatory properties of omega-3 fatty acids, this study aimed to evaluate
potential role of these fatty acids in improving anemia and inflammation of chronic HD patients.
Methods: In this randomized, placebo-controlled trial, 54 adult patients with HD duration of at least 3 months
were randomized to ingest 1800 mg of either omega-3 fatty acids or matching placebo per day for 4 months.
Anemia parameters including blood hemoglobin, serum iron, transferrin saturation (TSAT), erythropoietin
resistance index, and required dose of intravenous iron and erythropoietin, and serum concentrations of
inflammatory/anti-inflammatory markers including interleukin (IL)-6, tumor necrosis factor (TNF)-α, IL-10, C-reactive
protein (CRP), hepcidin, ferritin, intact parathyroid hormone (iPTH), and ratios of IL-10 to IL-6 and IL-10 to TNF-α
were measured at baseline and after 4 months of the intervention.
Results: 45 subjects (25 in the omega-3 and 20 in the placebo group) completed the study. No significant
changes were observed in blood hemoglobin, serum iron, TSAT, and required dose of intravenous iron in either
within or between group comparisons. Additionally, erythropoietin resistance index as well as required dose of
intravenous erythropoietin showed no significant change in the omega-3 group compared to the placebo group.
Although a relative alleviation in inflammatory state appeared in the omega-3 group, the mean differences of
inflammatory and anti-inflammatory markers between the two groups did not reach statistically significant level
except for IL-10-to-IL-6 ratio and serum ferritin level which showed significant changes in favor of omega-3
treatment (P <0.001 and P = 0.003, respectively).
Conclusion: Omega-3 fatty acids relatively improved systemic inflammation of chronic HD patients without any
prominent benefits on anemia. However, future well-designed studies on larger number of patients may
determine utility of omega-3 fatty acids in HD patients with respect to inflammation and anemia.
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Anemia occurs as one of the most common complications
of end-stage renal disease (ESRD) in patients undergoing
HD [1,2]. It is manifested typically as normocytic and nor-
mochromic anemia with normal cellularity of bone mar-
row [3]. Although erythropoietin (EPO) deficiency is the
major reason in the pathogenesis of anemia in ESRD pa-
tients, other factors including shortened erythrocyte sur-
vival, blood loss, iron and other nutritional deficiencies,
hemolysis, oxidative stress, and presence of uremic inhibi-
tors of erythropoiesis seem to play also important roles
[4]. Most patients with ESRD and anemia exhibit adequate
response to erythropoiesis-stimulating agents (ESA); how-
ever, about 10% of the subjects remain hypo- or non-
responsive to ESA [2]. Adequate iron supply is necessary
to obtain optimal benefit from the ESA therapy. Consider-
ing the accelerated erythropoiesis with the initiation of
ESA therapy combined with the ongoing uremia- and
dialysis-related iron losses, HD patients on ESA are highly
predisposed to development of iron-restricted erythropoi-
esis since the rate of iron release from stores and its deliv-
ery to erythroid marrow fail to supply the increased
marrow demand. Intravenous (IV) iron supplementation
can properly correct limited availability of iron to eryth-
roid marrow and improve hemoglobin concentration [1,5].
On the other hand, dialysis patients have a chronic in-
flammatory state which may contribute to iron-restricted
erythropoiesis via decreasing the mobilization of iron from
the reticulo-endothelial system to circulating transferrin, a
situation which is associated with the reduced response to
ESA therapy and IV iron supplementation [1,3,6]. Several
underlying factors have been noted to be responsible for
chronic systemic inflammation in HD patients, including
the uremic milieu, enhanced infection episodes, greater
generation of pro-inflammatory cytokines, widespread
atherosclerosis, and the use of bio-incompatible dialysis
membrane [3]. Recently, there has been an increasing at-
tention to inflammation in HD patients as a possible cause
of disordered iron homeostasis as well as anemia refrac-
tory to ESA treatment. Discovery of hepcidin, a 25-amino
acid peptide hormone mainly produced in the liver, has
dramatically increased our understanding of the molecular
basis of iron metabolism over the several past years. It is
regarded as the key regulator of iron entry into the sys-
temic circulation [7], and is up-regulated by increased iron
stores and inflammation and down-regulated by hypoxia,
anemia, and iron deficiency [3,8]. Hepcidin acts by binding
to cellular iron exporter ferroportin which is present on
the cell membrane of the enterocytes, macrophages and
hepatocytes and leads to its internalization and degrad-
ation [9]. Thus, the net effect of increased hepcidin syn-
thesis is the reduced absorption of dietary iron and
sequestration of iron in hepatocytes and macrophages. It
has been reported that dialysis patients have higher serumlevels of hepcidin [10-14], probably due to the impaired
renal excretion coupled with an enhanced generation sec-
ondary to inflammation and iron excess [15]. In addition
to limiting iron availability for erythropoiesis, hepcidin
may also contribute directly to ESA resistance by an in-
hibitory impact on erythroid progenitor proliferation and
survival [16].
Omega-3 fatty acids have been shown to provide dialysis
patients with a host of biochemical and clinical benefits
[17]. Nevertheless, it has been shown that dietary fish
consumption, as a main source of omega-3 fatty acids, in
chronic HD patients was much less than that recom-
mended by American Heart Association, resulting in sub-
optimal blood levels of omega-3 fatty acids [18]. Similarly,
significantly lower concentration of omega-3 fatty acids in
erythrocyte membrane phospholipids has been found in
HD patients compared with the healthy controls [19],
largely due to less consumption of fish or fish-derived prod-
ucts in this patient population [17]. However, the findings
of previous studies on anti-inflammatory effects of omega-3
fatty acids supplement in HD patients have been controver-
sial. Some of these studies have indicated positive effects of
oral omega-3 supplements on serum systemic inflamma-
tory markers [19-21], while others did not find these effects
[22,23]. Furthermore, there is report on positive [19] as
well as no effect [24] of oral omega-3 fatty acids on blood
hemoglobin level in maintenance HD subjects.
Taking all these data into consideration, our study was
aimed to test the hypothesis that administration of omega-
3 fatty acids (eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA)) in maintenance HD patients actually
improve systemic inflammation and anemia, and might be
useful for reducing serum hepcidin level and consequently
required dose of IV iron and EPO.Methods
Subjects
This is a prospective, randomized, single-blind, placebo-
controlled trial on patients in two HD centers in Iran
(Imam Khomeini Hospital Complex and Sina Hospital
affiliated to Tehran University of Medical Sciences,
Tehran, Iran). Adult patients who treated with HD for at
least 3 months were selected. Patients with pregnancy,
malabsorption syndrome, malignancy, inflammatory or
infectious diseases, hypothyroidism, medical or surgical
illness in recent 3 months, hemoglobinopathies, asthma,
chronic obstructive pulmonary disease, coagulopathies,
known psychiatric disorders, lack of tolerance or hyper-
sensitivity to fish products as well as those who were re-
ceiving corticosteroid, non-steroidal anti-inflammatory
drugs, omega-3 fatty acids in the previous three months,
anticoagulants including warfarin, immunomodulator or
immunosuppressive were excluded.
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The study used a 9-block permuted randomization proced-
ure to allocate subjects randomly into two groups. Each
block contained an equal number of omega-3 and control
group selections, with the order of the blocks permuted.
Random numbers to allocate blocks and randomize group
selection were generated using Microsoft Office Excel soft-
ware. All participants, care providers, and data monitors
were blinded to the identity of treatments throughout the
study. Patients enrolled into the study were randomized to
consume daily dose of either six soft-gel capsules of omega-
3 fatty acids (180 mg EPA and 120 mg DHA in each
capsule) or matching placebo (containing paraffin oil), pro-
vided by Zahravi pharmaceutical company, Tabriz, Iran, for
4 months. Both placebo and omega-3 soft-gel capsules were
the same with respect to the size, color, shape, and pack-
aging. All subjects were requested not to alter their habitual
diets, drug regimen, and level of physical activity during the
study. Adherence to the supplements was assessed by con-
ventional practice of “pill counting”, and interviewing with
each participant individually thrice weekly. Both omega-3
and placebo capsules were provided free of charge to
participants. Furthermore, an attending nephrologist per-
formed a monthly visit for each patient during a routine
HD session to encourage adherence to the recommended
supplement regimens, and to know adverse effects and tol-
erability of the supplements. Any changes in the medica-
tions as well as patient complaints were recorded during
the study period.
At baseline and the end of the study, 10 mL fasting
blood were obtained from each patient immediately before
HD initiation. The blood samples were centrifuged at
3000 rpm for 10 minutes to separate serum. Serum sam-
ples were kept frozen at −70°C for later analysis of serum
iron, total iron binding capacity (TIBC), ferritin, hepcidin,
iPTH, pro-inflammatory (IL-6, TNF-α, CRP), and anti-
inflammatory cytokines (IL-10) concentrations.
The local Ethics Committee of Tehran University of
Medical Sciences approved the study protocol, and in-
formed consent was obtained from each patient. The
trial was registered in the Iranian Registry of Clinical
Trials (registry number: IRCT201202203043N5).Measurements
Baseline dialysis adequacy (single pool Kt/V urea) was
measured for each subject according to pre- and post-
dialysis serum urea nitrogen concentrations, ultrafiltra-
tion volume, dialysis time, and post-dialysis weight.
Blood hemoglobin concentration was measured using
a cell counter (Sysmex K800, Japan); serum CRP level
was measured by a turbidimetric method (Autoanalyzer
BT3000, Biotechnica, Italy); serum hepcidin, IL-6, IL-10,
and TNF-α were measured using ELISA kits (BioassayTechnology laboratory, Shanghai Crystal Day Biotech Co.,
Ltd., Shanghai, China).
To evaluate the effect of omega-3 fatty acids on iron
status and EPO responsiveness, required dose of IV iron
and EPO was recorded monthly over the study course.
In addition, EPO resistance index (the ratio of weekly
EPO dose to hemoglobin concentration per unit of body
weight), as well as TSAT (calculated as serum iron ×
100/TIBC) were calculated before and after the 4-month
intervention period.
Statistical methods
Results were presented as means ± SD or medians (inter-
quartile range). The distribution normality of continuous
variables was investigated using quantile normal plot, nor-
mal probability plot, and Shapiro-Wilk test. Differences
between groups were analyzed using unpaired t-test or
two-sample Wilcoxon rank-sum (Mann–Whitney) test,
while paired t-test or Wilcoxon matched-pairs signed rank
test was used to compare differences within groups. The
chi-square test was used to compare differences between
categorical variables. Moreover, we estimated the effect of
omega-3 supplement on hemoglobin, hepcidin, ferritin,
TSAT, iPTH and EPO resistance index using the linear re-
gression model with omega-3 supplement as intervention
variable. To adjust for the difference in baseline values
and also demographic and clinical characteristics, we also
entered these variables in the model. Log-transformation
was made in case of TSAT before it was included in re-
gression analysis. Additionally, to normalize the amount
of IV EPO and iron required to correct anemia, square
root of them was created and then were included in re-
gression analysis. Due to non-normality and heterogeneity
of variances of the residual distributions, we used non-
parametric bootstrap method with 2000 replications to
obtain empirical standard errors and bias-corrected and
accelerated (BCa) confidence intervals. In addition, be-
cause required dose of IV iron and EPO were recorded
four times over the course of the study, to estimate the
time trend changes in intervention effect, we also fitted a
population-averaged panel-data model by using GEE (gen-
eralized estimation equation) with autoregressive one cor-
relation structure to account for within-group correlation
structure of individuals. P value of less than 0.05 or confi-
dence interval not including null value was considered as
statistically significant. All statistical analyses were carried
out using the SPSS version 16.0 (SPSS, Inc., Chicago, IL,
USA) and Stata software (StataCorp. 2011. Stata Statistical
Software: Release 12. College Station, TX: StataCorp LP).
Results
Figure 1 presents patient randomization and participa-
tion procedure in the study. Sixty-four patients were
qualified for the study. Of those, 54 patients accepted to
Subjects screened for 
qualification (n = 155)
Excluded (n = 101) 
Not eligible (n = 91)
Unwillingness to participate (n =10)
Omega-3 (n = 27)Placebo (n = 27)
Patient dropout (n = 2)
Noncompliance with the 
study protocol (n = 1)
Surgery (n = 1)
Patient dropout (n = 7)
Hospitalization (n = 1)
Undergoing kidney 
transplantation (n = 1)
Unwillingness to take large 
capsule (n = 2)
Death due to coronary heart 
disease (n = 1)
HD centers change (n =2)
Randomized (n = 54)
Final analysis on study 
completer (n = 25)
Final analysis on study 
completer (n = 20)
Figure 1 Study’s flowchart indicating patient randomization and participation.
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placebo and 2 in the omega-3 group) over the course of
the study and thus, 45 (20 placebo and 25 omega-3) com-
pleted the study, and their data were used in the final
analysis. Table 1 summarizes baseline characteristics of
subjects who completed the study. Demographic (gender
and age) and clinical (HD duration, dialysis adequacy, andTable 1 Patients’ demographic and clinical data at baseline in
Characteristics Placebo (n = 20)




Hemodialysis duration (mo) (± SD) 72.05 (±60.51)
Dialysis adequacy (Kt/V) 1.27 ± 0.15
Cause of end-stage renal disease, n (%)
Diabetes 7 (35)
Hypertension 8 (40)
Other causes 5 (25)
Note: Age and hemodialysis duration are expressed as mean ± SD.underlying causes of ESRD) data of the patients were com-
parable between the two study groups at baseline.
Blood hemoglobin levels decreased in both groups dur-
ing the study period with more decrease in the placebo
group. However, the amount of reduction was not signi-
ficantly different between the two groups (P = 0.316). In
addition, although serum iron and TSAT showed anthe placebo and omega-3 group
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group, the magnitude of changes did not reach statistically
significance level between the two groups (Table 2). Mean
serum TIBC significantly decreased in the omega-3 group
at the end of month 4 compared with the placebo group
(P = 0.025). It is worth noting that before within and
between group comparisons were performed on serum
hepcidin, four major outlying values were excluded (2 from
each group) since they were outside the assay range spe-
cified in the package insert of hepcidin kit (> 4000 pg/mL).
Thereafter, we observed that serum hepcidin level re-
mained unchanged in the placebo group (P = 0.756) at the
end of the study compared with baseline, whereas its level
increased significantly in the omega-3 group (P = 0.048).
However, the mean difference of serum hepcidin were
comparable between the two groups (P = 0.145).
Our results demonstrated that omega-3 treated group
had less inflammatory state than placebo group at the
end of the study, as reflected in the serum concentra-
tions of IL-6, TNF-α, IL-10, CRP, and anti-inflammatory
to pro-inflammatory ratios of IL-10 to TNF-α and IL-10
to IL-6. Although serum levels of iPTH and ferritin, as
surrogates of systemic inflammation, increased in both
study arms during the study, omega-3 treated subjects
experienced much less increase than placebo group.
Additionally, comparison of mean differences between
the two groups became significant with respect to only
serum ferritin level and IL-10 to IL-6 ratio (Table 2).
As shown in Table 3, EPO resistance index showed no
significant changes in the omega-3 group compared with
the placebo group at the end of the study (P = 0.086). At
the same time, population-averaged panel-data model did
not show any significant change in the required dose of
both IV EPO and iron between the two groups in four
months of follow-up (Table 4). Of note, omega-3 treat-
ment was weakly and negatively associated with month
four IV EPO dose over the course of the study (P = 0.087),
whereas no such a finding was found regarding the rela-
tion between omega-3 treatment and required IV iron
dose (Table 4).
Regression analysis with bootstrap method illustrated
that among anemia parameters studied in this study,
omega-3 treatment was a significant predictor of only
serum ferritin level after adjustment for patients’ base-
line demographic and clinical characteristics (Table 5).
Discussion
Anemia occurs as a common complication in patients
with chronic kidney disease and associated with a poor
quality of life and bothersome symptoms including fatigue,
headache, dyspnea, and light-headedness [25]. Notably, it
contributes to the high prevalence of left ventricular
hypertrophy in chronic kidney disease patients, even prior
to the onset of dialysis, which has been associated withcardiovascular mortality [26]. Thus, careful detection and
treatment of anemia is of clinical importance in dialysis
patients.
We aimed to investigate the potential benefits of omega-
3 fatty acids as adjunct to IV iron and EPO treatment in
correction of anemia in maintenance HD patients. Our
study showed that administration of omega-3 fatty acids for
4 months caused no change in blood hemoglobin level.
This finding was in line with that of Kooshki et al.’s study,
in that they showed no significant change in blood
hemoglobin level following a 10-week supplementation of
HD patients with 2080 mg omega-3 fatty acids per day
[24]. Additionally, Donnelly et al. illustrated that daily in-
gestion of 3.6 g omega-3 fatty acids by HD patients for 4
weeks produced no significant change in blood hemoglobin
concentration [27]. Conversely, Perunicic-Pekovic et al. in-
dicated that daily supplementation of HD patients with 2.4
g omega-3 fatty acids for 8 weeks caused a significant
increase in blood hemoglobin concentration [19]. The
observed discrepancies may in part be related to the diver-
sity in study design, duration and dosage of omega-3 sup-
plementation, varied dietary intake, and baseline blood
hemoglobin concentration of the patients.
Supplemental use of omega-3 fatty acids for 4 months
also failed to increase TSAT as representative of available
serum iron for erythropoiesis. Although we found no
similar study in available literature regarding the effect
of omega-3 fatty acids on available serum iron to be
compared with our results, it seems that inability of
omega-3 supplement to improve TSAT might be related
to lower dosage of omega-3 supplement (1800 mg per
day), relatively favorable TSAT at baseline, or uncon-
trolled dietary intake of iron.
Moreover, serum TIBC showed a significant reduction
in the omega-3 group compared to the placebo group over
the course of the study. This finding was in contrast to
that of Kalantar-Zadeh et al.’s study, in which they ob-
served a significant increase in serum TIBC in hypoalbu-
minemic HD patients who consumed a nutritional oral
supplement containing 1680 mg omega-3 fatty acids [28].
Although the supplement was used during each HD ses-
sion for 4 weeks, the complex composition of the supple-
ment makes it impossible to distinguish the potential
positive effect of omega-3 fatty acids on serum TIBC from
other constituents. In addition, Szklarek-Kubicka et al.
found no marked effects of intradialytic intravenous ad-
ministration of omega-3 emulsion (containing 2g EPA and
2g DHA) on serum transferrin after 11 consecutive HD
sessions [29]. Because dietary protein intake can influence
serum transferrin concentration, as a correlate of TIBC,
uncontrolled patients’ diet in our study might have led to
this controversial result. Altogether, considering no signifi-
cant change in TSAT along with relative attenuated in-
flammatory state in the omega-3 group, conflicting result
Table 2 Effects of 4 months omega-3 vs. placebo supplementation on hematological and inflammatory parameters
Placebo (n = 20) Omega-3 (n = 25)
Baseline Month-4 Diff P Baseline Month-4 Diff P P overall
Hgb (g/dL)
Mean ± SD 11.14 ± 1.62 10.17 ± 1.62 −0.97 ± 2 0.055 11.14 ± 2.27 10.86 ± 1.30 −0.28 ± 2.21 0.567 0.316
Median (IQR) 10.90 (10.10, 12.30) 10.40 (9.02, 11.20) 11.10 (9.45, 12.15) 10.70 (10, 11.45)
Serum iron (μg/dL)
Mean ± SD 86.11 ± 37.52 87 ± 43.44 0.89 ± 49.23 117.45 ± 117.65 71.85 ± 48.05 −45.60 ± 115.34
Median (IQR) 80 (54.25, 109.50) 66 (53, 132.75) 0.647 66 (48.25, 113.25) 52.50 (45.50, 96) 0.296 0.781
TIBC (μg/dL)
Mean ± SD 281 ± 78.09 264 ± 95.29 −17 ± 125.98 318.81 ± 75.26 224.60 ± 52.23 −94.21 ± 77.28 0.000 0.025
Median (IQR) 252.50 (234.50, 297.50) 232 (200, 283.25) 0.446 310 (255, 383) 210 (182, 272)
TSAT%
Mean ± SD 33.36 ± 16.99 38.56 ± 26.20 5.20 ± 28.06 35.15 ± 29.12 32.77 ± 22.19 −2.37 ± 30.49
Median (IQR) 30.41 (19.70, 45.80) 29.19 (18.62, 53.28) 0.711 23.67 (14.08, 42.29) 25.68 (17.65, 42.26) 0.575 1.000
Ferritin (ng/mL)
Mean ± SD 345.91 ± 168.90 1236 ± 885.85 890.05 ± 862.71 839.63 ± 719.81 1005.10 ± 1185.70 165.45 ± 886.59
Median (IQR) 445.50 (187, 467.50) 1033 (750, 1767) 0.000 696.50 (213.25, 1225.80) 739.50 (126, 1267.50) 0.681 0.000
Hepcidin (pg/mL)
Mean ± SD 584.81 ± 654.45 557.25 ± 401.96 −27.56 ± 650.83 579.74 ± 340.81 729.48 ± 661.81 149.74 ± 574.87
Median (IQR) 358.50 (306.50, 546.50) 377 (334.50, 812.25) 0.756 392 (318, 983) 443 (335, 856) 0.048 0.145
IL-6 (ng/L)
Mean ± SD 103.54 ± 145.18 106.48 ± 136.51 2.94 ± 206.17 144.38 ± 167.66 136.85 ± 183.56 −7.53 ± 126.01
Median (IQR) 44.90 (40.22, 87.32) 52.85 (40.55, 98.62) 0.695 56.30 (46.90, 151.45) 50 (29.20, 123.50) 0.034 0.115
TNF-α (ng/L)
Mean ± SD 80.93 ± 64.89 77.43 ± 59.82 −3.50 ± 49.21 122.09 ± 171.69 116.57 ± 172.32 −5.52 ± 46.92
Median (IQR) 48.05 (42.42, 95.57) 48.05 (44.17, 99.22) 0.616 67 (44.30, 127.20) 58.60 (44.55, 112.80) 0.346 0.971
IL-10 (pg/mL)
Mean ± SD 111.76 ± 67.39 107.24 ± 63.01 −4.51 ± 90.79 123.94 ± 71.91 132.06 ± 94.81 8.11 ± 57.63
Median (IQR) 78.05 (72.80, 119.08) 83 (68.20, 128.30) 0.446 91.80 (71.80, 154.10) 87.70 (69.90, 149.60) 0.798 0.445
IL-10 / IL-6
Mean ± SD 1.57 ± 0.42 1.39 ± 0.35 −0.18 ± 0.53 1.32 ± 0.55 1.96 ± 1.19 0.64 ± 1.14



















Table 2 Effects of 4 months omega-3 vs. placebo supplementation on hematological and inflammatory parameters (Continued)
IL-10 / TNF-α
Mean ± SD 1.85 ± 1.19 1.69 ± 0.95 −0.16 ± 1.17 1.35 ± 0.29 1.44 ± 0.28 0.09 ± 0.25 0.399
Median (IQR) 1.62 (1.26, 2.07) 1.49 (0.91, 2.08) 0.349 1.39 (1.20, 1.58) 1.50 (1.27, 1.64) 0.139
CRP (mg/L)
Mean ± SD 7.73 ± 4.89 12.69 ± 14.02 4.96 ± 12.59 9.24 ± 8.79 8 ± 6.78 −1.24 ± 5.68
Median (IQR) 6.19 (4.79, 8.93) 6.26 (3.55, 18.81) 0.246 6.23 (4.87, 10.26) 5.91 (3.25, 10.72) 0.414 0.143
iPTH (pg/mL)
Mean ± SD 271.18 ± 233.60 654.57 ± 1082.30 383.39 ± 927.49 333.42 ± 567.22 348.07 ± 723 14.65 ± 235.88
Median (IQR) 180 (95, 507.50) 224 (110.40, 980.50) 0.006 118 (91.35, 316) 167 (97.15, 286) 0.455 0.17
Notes: Data are mean ± SD and median (IQR). P values for each group were derived from paired t-test or Wilcoxon signed ranks test between baseline versus month-4 comparison (within group comparison). Overall P
values were derived using independent t-test or Mann–Whitney U test, comparing mean differences of parameters between omega-3 and placebo group (between group comparisons of mean differences)
(bold faces).
Abbreviations and definitions: IQR, Interquartile range; IL, Interleukin; TNF-α, Tumor necrosis factor alpha; CRP, C-reactive protein; iPTH, Intact parathyroid hormone; Hgb, Hemoglobin; TSAT, Transferrin saturation; TIBC,



















Table 3 Mean dose of IV iron and EPO and calculated EPO resistance index in two groups
Groups Baseline Month 2 Month 3 Month 4 Difference P value
IV iron (mg/week)
Omega-3 65.22 ± 91.93 49 ± 63.11 37 ± 61.29 37.30 ± 76.78 −27.91 ± 128.96 0.554
Placebo 54.17 ± 44.76 36.84 ± 34.73 56.94 ± 71.13 23.61 ± 33.73 −30.56 ± 64.49
IV EPO (unit/week)
Omega-3 8695.70 ± 8059 9960 ± 7236.90 8640 ± 7846.80 8956.50 ± 8019.70 260.87 ± 4013.81 0.086
Placebo 6888.90 ± 4861.40 9052.60 ± 4440.60 8333.30 ± 4186.80 9666.70 ± 5005.80 2777.78 ± 5493.91
EPO resistance index (unit/week per Hgb per weight)
Omega-3 14.64 ± 15.12 - - 15.03 ± 13.40 0.39 ± 7.82 0.086
Placebo 11.17 ± 8.72 - - 17.26 ± 12.02 6.09 ± 11.89
Notes: All values are mean ± SD. Difference indicates mean difference of month-4 minus baseline. P values were derived using independent t-test or Mann–Whitney
U test, comparing mean differences of parameters between two groups (bold faces). P value < 0.05 was considered as statistically significant.
Abbreviations: Hgb Hemoglobin, IV Intravenous, EPO Erythropoietin.
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studies.
In the present work, serum ferritin level increased in
both groups during the study period with much more
retarded increase in the omega-3 group. In contrast,
Rasic-Milutinovic et al. showed that daily administration
of 2.4 g omega-3 fatty acids for 8 weeks significantly low-
ered serum ferritin level in maintenance HD patients [21].
Huang et al. failed to demonstrate an association between
plasma omega-3 fatty acids concentration and systemic in-
flammation in dialysis patients [30]. We used a moderate
dose of 1800 mg omega-3 supplement per day for 4
months, which may be insufficient to replace membrane
phospholipids’ fatty acids beside plasma free fatty acids to
exert prominent anti-inflammatory effects. However,
omega-3 supplement in our study was a significant and in-
dependent predictor of reduction in serum ferritin. Given
the unchanged TSAT in both arms of this study, it is con-
ceivable that changes in serum ferritin, as an acute phase
protein, was more reflective of systemic inflammation ra-
ther than iron stores. This concept was further supported
when serum ferritin increased more restrictedly in omega-Table 4 Population-averaged panel-data model by using GEE
quired dose of IV iron and EPO during the study, with time b
Dependent variable Omega-3† Baseline v
β = −15.57 β = 0.48
Post-IV EPO dose 95%CI (−32.93 , 2.93) 95%CI (0.2
P = 0.087 P = 0.000
β = −0.42 β = 0.18
Post-IV iron dose 95%CI (−3.13 , 2.59) 95%CI (−0.
P = 0.771 P = 0.166
Notes: Square root of intravenous erythropoietin and iron were included in regressi
Abbreviations: EPO Erythropoietin, IV Intravenous, Post- Post-intervention, TSAT Trans
†The coefficient indicates predictive value of omega-3 treatment on the difference
omega-3 and placebo groups.
P value < 0.05 or 95%CI not including null value was considered as statistically sign3 treated patients who experienced slight alleviation in
systemic inflammation (Table 2).
The mean difference of required IV EPO dose in the
omega-3 group was lower than that in the placebo group
(Table 3). Consistently, population-averaged panel-data
model revealed that omega-3 supplement was a weakly
predictor of reduced IV EPO dose in month four of inter-
vention. Therefore, more pronounced reduction in IV
EPO dose might likely appear with omega-3 supplementa-
tion if the study period was expanded. In contrast,
Kooshki et al. found no significant changes in mean dose
of IV EPO in either omega-3 (2080 mg/day) or placebo
group during their 10-week study period [24]. In our
study, EPO resistance index indicated no significant im-
provement in omega-3 treated subjects compared with the
placebo group during the study period. In contrast to this
finding, Himmelfarb et al. demonstrated that daily adminis-
tration of gamma-tocopherol-enriched mixture of DHA
(containing 924 mg gamma-tocopherol and 1200 mg
DHA) for 8 weeks caused a significant reduction in the
serum IL-6 and erythropoietic index (weekly EPO dose di-
vided by hematocrit) in maintenance HD patients [31]. Infor evaluating the effects of omega-3 supplement on re-
eing considered as a possible interacting factor
Independent variables
alue Time Time*Omega-3
β = 1.71 β = −7.04
7 , 0.68) 95%CI (−3.24 , 6.36) 95%CI (−17.52 , 2.29)
P = 0.493 P = 0.150
β = −0.73 β = 0.18
03 , 0.45) 95%CI (−1.94 , 0.66) 95%CI (−1.67 , 2.21)
P = 0.279 P = 0.856
on analysis.
ferrin saturation, CI Bias-corrected confidence interval.
in square root of outcome variables measured at the end of the study between
ificant.









Coefficient (β) 0.683 67.979 −922.484 −0.273 −5.404 −414.247
Bootstrap
standard error
0.547 147.169 282.992 0.218 3.899 213.935
P value 0.212 0.644 0.001* 0.211 0.166 0.053
95% CI (−0.361, 1.776) (−203.593, 362.789) (−1533.274, -412.422) (−0.671, 0.193) (−12.844, 2.466) (−1150.008, -129.641)*
Abbreviations: EPO Erythropoietin, Post- Post-intervention, TSAT Transferrin saturation, iPTH Intact parathyroid hormone, CI Bias-corrected and accelerated
confidence interval.
†All analyses were adjusted for age, gender, hemodialysis duration, and baseline values of Kt/V and outcome variables.
ΨBoth baseline and post-intervention TSAT were included in regression analysis in logarithmic scale.
*P value < 0.05 or 95%CI (with bootstrap method) not including null value was considered as statistically significant.
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resistance [32-34], relative attenuated inflammation by
omega-3 supplement in our study was not sufficient to
cause favorable changes in EPO resistance.
Unexpectedly, required dose of IV iron decreased in
both groups through the study period with no significant
difference between the mean differences of the two groups
(Table 3). Additionally, population-averaged panel-data
model showed no role of omega-3 supplement over time
in the prediction of post-treatment IV iron dose. Unfortu-
nately, we were not able to interpret such a finding using
available data.
In our study, although omega-3 treated patients experi-
enced significant increase in the ratio of IL-10 to IL-6 and
marked favorable changes in the serum ferritin level com-
pared to the placebo group, other serum inflammatory
markers including IL-6, TNF-α, CRP, IL-10, iPTH and IL-
10-to-TNF-α ratio also desirably changed in this group.
Inability of omega-3 supplement to provide marked anti-
inflammatory effects in this study may be due to limited
statistical power, small dosage of omega-3 fatty acids sup-
plement, shorter observation period, or all of these. It
should be mentioned that results of the majority of the
studies evaluating the effects of omega-3 fatty acids on in-
flammatory markers in HD patients are inconclusive,
largely due to diversity in study design, supplement dos-
age, and study length. Saifullah et al. showed that daily ad-
ministration of 1.3 g omega-3 fatty acids for 12 weeks
induced a significant reduction in serum CRP levels of HD
patients [20]. In addition, Perunicic-Pekovic et al. demon-
strated significant decline in serum IL-6 and TNF-α levels
of HD subjects following daily consumption of 2.4 g of
omega-3 fatty acids for 2 months [19]. Bowden et al.
treated maintenance HD patients with 1560 mg omega-3
fatty acids per day for 6 months, and found a significant
decrease in serum CRP level [35]. In contrast, a recent
study by Kooshki et al. failed to demonstrate any effects of
omega-3 fatty acids (2080 mg per day for 10 weeks) on
serum CRP, TNF-α, and IL-6 concentration in HD patients
[36]. In agreement with our results, Hassan et al. foundinsignificant decrease in the serum concentrations of CRP,
TNF-α, and IL-6 after 8 weeks of oral omega-3 supple-
mentation (3.4 g EPA and DHA per day) in peritoneal dia-
lysis patients [37]. Also our results were in line with those
of Poulia et al.’s study, that daily ingestion of 1680 mg
omega-3 fatty acids for 4 weeks caused an insignificant
decline in serum CRP concentrations in chronic HD sub-
jects [38].
Additionally, omega-3 supplement was a significant
predictor of reduced serum iPTH level in our study
(Table 5). None of the participants ingested cinacalcet to
control hyperparathyroidism, and the number of sub-
jects receiving calcitriol was comparable between the
two study arms. Thus, significant association of omega-3
supplementation with reduced serum iPTH levels might
largely be related to partial decline in systemic inflam-
mation following 4 months of omega-3 administration.
In addition, serum hepcidin level showed no signi-
ficant change in the omega-3 group compared with
the placebo group. There are conflicting reports with re-
spect to the relation between inflammation markers and
serum hepcidin. Some studies have detected a positive
association [39,40], while others have not [15,41,42].
Our study showed a relative improvement in systemic
inflammation by omega-3 treatment, whereas serum
hepcidin level showed a significant increase in this
group. Also TSAT, as an important regulator of hepcidin
synthesis [43], had no significant changes within and be-
tween the two groups during the study period. Actually,
we found no similar study in available literature regard-
ing the effect of omega-3 supplement on serum hepcidin
to compare our result. However, some reasons could be
provided for the observed discrepancy. First, dosage of
omega-3 fatty acids used in our study might not be suffi-
cient to exert pronounced suppression on systemic in-
flammatory markers in general, and serum hepcidin in
particular. Second, considering normal value of inflam-
mation markers in healthy individuals [44,45], our study
subjects had no overt sever inflammation at baseline or
at the end of the study, that this state might partly
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on hepcidin production. Third, elevated serum hepcidin
may not be necessarily needed to maintain a mild iron defi-
ciency and anemia of inflammation because other inflam-
matory mediators have a similar effect, and normal serum
hepcidin level is also able to sufficiently restrict iron supply
and prevent the correction of the established anemia [41].
Finally, interrelations among the response to EPO, serum
iron status, iron therapy, and serum hepcidin increase the
complexity of interpretations in this area. For instance,
some iron parameters are representative of both iron stores
and inflammation (i.e. ferritin) or have a mixed inflamma-
tory and nutritional significance (i.e. transferrin) [46,47].
Our study may be criticized for some limitations, as fol-
lows: low statistical power to detect meaningful differences
between the groups due to the small sample size and short
observation period, monitoring of patient compliance with
“pill counting” practice instead of in vivo measurement of
omega-3 fatty acids, lack of interim analysis on all out-
come variables to identify a potential trend over time and
reduce variance of estimates of treatment effects, distor-
tion of subject blindness in the placebo arm due to “Fishy”
smells of omega-3 soft-gel capsules, and lack of careful
assessment of patients’ dietary intake. Despite the above-
mentioned limitations, our trial had several strengths
including placebo-controlled design, relatively longer dur-
ation of the study compared with previous ones, relatively
comprehensive assessment of anemia and inflammation
markers, absent serious adverse effects causing patient
withdrawal, and enhanced patient adherence via more fre-
quent interviews compared with previous studies.
In summary, the present study showed a mild attenu-
ation in systemic inflammation of chronic HD patients by
omega-3 fatty acids supplement. Although omega-3 sup-
plement failed to improve anemia, its positive, though
slight, effects on serum inflammation markers including
ferritin were encouraging. Considering elevated serum
hepcidin in the presence of unchanged TSAT and weak-
ened inflammation in the omega-3 group, it can be specu-
lated that other impressive factor(s) not controlled in our
study might contribute to these contradictory results.
Therefore, there is a need for further well-designed studies
to precisely determine utility of omega-3 fatty acids in HD
patients with respect to inflammation and anemia.
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